Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosamprenavir/Ritonavir Dosing with Epzicom in HIV
NCT00335270Phase 4Completed
- Sponsor
- Duke University
- Start
- Mar 2006
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fosamprenavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Duke University. Primary endpoints: Proportion of subjects with plasma HIV 1 RNA <400 copies at 48 weeks and Proportion of subjects who experience drug related discontinuations at 48 weeks. Started Mar 2006; status: completed.
02
Drugs
fosamprenavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00335270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00335270.